143 related articles for article (PubMed ID: 35585014)
1. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry.
Meagher MF; Mir MC; Autorino R; Minervini A; Kriegmair M; Maurer T; Porpiglia F; Van Bruwaene S; Linares E; Hevia V; Musquera M; Roussel E; Pavan N; Antonelli A; Zhang S; Ghali F; Patel D; Javier-Desloges J; Bradshaw A; Rubio J; Guruli G; Tracey A; Campi R; Albersen M; Furlan M; McKay RR; Derweesh IH
Clin Genitourin Cancer; 2022 Aug; 20(4):326-333. PubMed ID: 35585014
[TBL] [Abstract][Full Text] [Related]
2. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
[TBL] [Abstract][Full Text] [Related]
3. Metastatic renal cell carcinoma to the pancreas: Clinical features and treatment outcome.
Shin TJ; Song C; Jeong CW; Kwak C; Seo S; Kang M; Chung J; Hong SH; Hwang EC; Park JY; Lee H
J Surg Oncol; 2021 Jan; 123(1):204-213. PubMed ID: 33047324
[TBL] [Abstract][Full Text] [Related]
4. Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy.
Meagher MF; Minervini A; Mir MC; Cerrato C; Rebez G; Autorino R; Hampton L; Campi R; Kriegmair M; Linares E; Hevia V; Musquera M; D'Anna M; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Marchioni M; Paksoy N; Erdem S; Derweesh IH
Eur Urol Open Sci; 2024 May; 63():71-80. PubMed ID: 38572300
[TBL] [Abstract][Full Text] [Related]
5. Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 ("Oligometastatic") and M2 ("Polymetastatic") subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC).
Meagher MF; Mir MC; Minervini A; Kriegmair M; Heck M; Porpiglia F; Van Bruwaene S; Linares E; Hevia V; D'Anna M; Veccia A; Roussel E; Claps F; Palumbo C; Marchioni M; Afari J; Saitta C; Liu F; Rubio J; Campi R; Mari A; Amiel T; Checcucci E; Musquera M; Guruli G; Pavan N; Albersen M; Antonelli A; Klatte T; Autorino R; McKay RR; Derweesh IH
Front Oncol; 2023; 13():1113246. PubMed ID: 37064092
[TBL] [Abstract][Full Text] [Related]
6. Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).
Marchioni M; Kriegmair M; Heck M; Amiel T; Porpiglia F; Ceccucci E; Campi R; Minervini A; Mari A; Van Bruwaene S; Linares E; Hevia V; Musquera M; D'Anna M; Derweesh I; Bradshaw A; Autorino R; Guruli G; Veccia A; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Palumbo C; Klatte T; Erdem S; Mir MC;
Eur Urol Oncol; 2021 Apr; 4(2):256-263. PubMed ID: 33384274
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience.
Dragomir A; Nazha S; Wood LA; Rendon RA; Finelli A; Hansen A; So AI; Kollmannsberger C; Basappa NS; Pouliot F; Soulières D; Heng DYC; Kapoor A; Tanguay S
Urol Oncol; 2020 Oct; 38(10):799.e1-799.e10. PubMed ID: 32778475
[TBL] [Abstract][Full Text] [Related]
8. Metastasectomy Improves Overall Survival in Metastatic Renal Cell Carcinoma: A Retrospective Cohort Study.
Chiou JK; Chang LW; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Cheng CL; Chiu KY; Hung SC
Anticancer Res; 2023 Jul; 43(7):3193-3201. PubMed ID: 37351976
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era.
Takagi T; Fukuda H; Ishihara H; Yoshida K; Kondo T; Kobayashi H; Iizuka J; Okumi M; Ishida H; Omae K; Tanabe K
Urol Oncol; 2020 May; 38(5):515-520. PubMed ID: 32146128
[TBL] [Abstract][Full Text] [Related]
10. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
[TBL] [Abstract][Full Text] [Related]
11. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.
Verbiest A; Couchy G; Job S; Caruana L; Lerut E; Oyen R; de Reyniès A; Tosco L; Joniau S; Van Poppel H; Van Raemdonck D; Van Den Eynde K; Wozniak A; Zucman-Rossi J; Beuselinck B
Eur Urol; 2018 Oct; 74(4):474-480. PubMed ID: 29463434
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
Urol Oncol; 2021 Jan; 39(1):77.e17-77.e25. PubMed ID: 32863124
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Site-Specific Metastases and Therapeutic Roles of Surgery and Chemotherapy for Patients With Metastatic Renal Pelvis Cancer: A SEER Based Study.
Chen WK; Wu ZG; Xiao YB; Wang QQ; Yu DD; Cai J; Zhou CF
Technol Cancer Res Treat; 2021; 20():15330338211004914. PubMed ID: 33929915
[TBL] [Abstract][Full Text] [Related]
14. A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma.
Kim SH; Park WS; Park B; Pak S; Chung J
Front Oncol; 2019; 9():413. PubMed ID: 31179242
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
Stühler V; Herrmann L; Maas M; Walz S; Rausch S; Stenzl A; Bedke J
World J Urol; 2022 May; 40(5):1175-1183. PubMed ID: 35217885
[TBL] [Abstract][Full Text] [Related]
16. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma.
You D; Lee C; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2331-8. PubMed ID: 27553579
[TBL] [Abstract][Full Text] [Related]
17. Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis.
Maisel F; Smolle MA; Mollnar S; Riedl JM; Barth DA; Seles M; Terbuch A; Rossmann CH; Eisner F; Mannweiler S; Hutterer G; Zigeuner R; Pummer K; Smolle-Jüttner FM; Lindenmann J; Stotz M; Gerger A; Jost PJ; Bauernhofer T; Pichler M; Posch F
Clin Genitourin Cancer; 2022 Aug; 20(4):344-353. PubMed ID: 35443915
[TBL] [Abstract][Full Text] [Related]
18. Surgical treatment of atypical metastasis from renal cell carcinoma (RCC).
Antonelli A; Arrighi N; Corti S; Legramanti S; Zanotelli T; Cozzoli A; Cunico SC; Simeone C
BJU Int; 2012 Dec; 110(11 Pt B):E559-63. PubMed ID: 22639956
[TBL] [Abstract][Full Text] [Related]
19. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
20. The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Hsieh PY; Hung SC; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Cheng CL; Chiu KY
Urol Oncol; 2021 Jul; 39(7):422-430. PubMed ID: 33934963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
